Antihypertensive Drugs

Angiotensin converting enzyme inhibitors or angiotensin receptor blockers are the preferred first-line agents in most patients with diabetes, particularly when any degree of albuminuria is present. They reduce intraglomerular pressure through efferent arteriolar dilation, providing renoprotection independent of blood pressure lowering. They also reduce the incidence of new-onset type 2 diabetes versus beta-blockers and thiazides by approximately 20 to 25 percent, reflecting improved insulin receptor signaling when angiotensin II-mediated interference is removed.

Angiotensin converting enzyme inhibitors are preferred in type 1 diabetic nephropathy — the Lewis et al. (1993) captopril trial established 50 percent reduction in doubling of serum creatinine and end-stage renal disease. Angiotensin receptor blockers are preferred in type 2 diabetic nephropathy — the RENAAL (losartan) and Irbesartan Diabetic Nephropathy Trial (irbesartan) trials have Food and Drug Administration approval for this indication. Either class is appropriate for hypertension without significant proteinuria when tolerability and cost guide selection. Dual renin-angiotensin-aldosterone system blockade combining angiotensin converting enzyme inhibitor plus angiotensin receptor blocker is contraindicated — the VA NEPHRON-D trial showed excess acute kidney injury and hyperkalemia with no benefit.

Calcium channel blockers are metabolically neutral — no adverse effects on glucose metabolism, insulin sensitivity, or lipids — and highly effective in diabetic hypertension. Amlodipine is the preferred dihydropyridine calcium channel blocker, supported by the ACCOMPLISH trial demonstrating superior cardiovascular outcomes versus renin-angiotensin-aldosterone system inhibitor plus hydrochlorothiazide. Calcium channel blockers are equally effective in Black patients with diabetes as in other groups. In patients with significant albuminuria, dihydropyridine calcium channel blockers have less antiproteinuric effect than renin-angiotensin-aldosterone system inhibitors and should be combined with rather than substituted for renin-angiotensin-aldosterone system inhibitors.

Thiazide and thiazide-like diuretics are effective in diabetic hypertension but require careful attention to metabolic effects. At low doses — chlorthalidone 12.5 mg, hydrochlorothiazide 12.5 to 25 mg, indapamide 1.25 mg — glucose effects are acceptable and manageable. Indapamide has the most favorable metabolic profile and is essentially glucose-neutral at standard doses. At higher doses, hypokalemia impairs insulin secretion from pancreatic beta cells, worsening glycemic control. The practical approach is to use the lowest effective dose, prefer chlorthalidone or indapamide over hydrochlorothiazide, and pair with a renin-angiotensin-aldosterone system inhibitor to blunt hypokalemia. Loop diuretics are required when estimated glomerular filtration rate falls below 30 mL/min.

Beta-blockers carry important metabolic risks in diabetes through beta-2 blockade: impaired insulin secretion from pancreatic beta cells, impaired glycogenolysis delaying hypoglycemia recovery, and masking of most hypoglycemic warning symptoms (diaphoresis is preserved because it is cholinergically mediated). Non-selective agents also raise triglycerides and lower high-density lipoprotein.

Beta-blockers remain indicated when a compelling indication exists — heart failure with reduced ejection fraction, post-myocardial infarction, atrial fibrillation rate control, or angina. When required in a patient with diabetes, agent selection matters significantly. Carvedilol (combined alpha/beta-blocker) is metabolically neutral to favorable and does not worsen insulin resistance — the preferred choice in most patients with diabetes needing a beta-blocker. Nebivolol (cardioselective with nitric oxide-mediated vasodilation) has the least metabolic impact of all beta-blockers. Bisoprolol has acceptable glucose effect at standard doses with once-daily simplicity. Atenolol should be avoided — the LIFE trial demonstrated inferior cardiovascular outcomes versus losartan, it carries a substantial metabolic burden, and it accumulates in chronic kidney disease.

Diabetes-specific drivers of resistance include greater salt sensitivity and volume retention from renal sodium avidity; higher prevalence of aldosterone excess (including primary aldosteronism and hyperaldosteronism from insulin resistance); obstructive sleep apnea present in approximately 80 percent of patients with resistant hypertension and particularly prevalent in obese patients with type 2 diabetes; more complex medication regimens with adherence challenges; and chronic kidney disease-related volume retention. Nonsteroidal anti-inflammatory drugs are frequently used in diabetic patients for peripheral neuropathy pain and musculoskeletal comorbidities — they raise blood pressure by 3 to 5 millimeters of mercury on average and blunt both diuretic and renin-angiotensin-aldosterone system inhibitor efficacy. Reviewing all medications for this interaction is essential.

Spironolactone 25 to 50 mg daily remains the most effective fourth-line agent per the PATHWAY-2 trial and should be the first choice when tolerated — potassium requires close monitoring. Eplerenone should be substituted if gynecomastia or sexual dysfunction occurs with spironolactone. In type 2 diabetic chronic kidney disease with residual albuminuria on renin-angiotensin-aldosterone system inhibitor plus sodium-glucose cotransporter 2 inhibitor, finerenone 10 to 20 mg is the preferred mineralocorticoid receptor antagonist given its dual cardiovascular and renal outcome evidence from FIDELIO-DKD and FIGARO-DKD with lower hyperkalemia risk than steroidal agents. Doxazosin is an alternative fourth-line agent that is metabolically neutral and beneficial in men with concurrent benign prostatic hyperplasia. Bisoprolol or nebivolol should be considered if a beta-blocker indication exists and one is not already prescribed.